Allergen immunotherapy / Stallergenes - LARVOL DELTA

Long-term impact of a birch/alder/hazel or birch-only liquid sublingual immunotherapy on birch-family pollen respiratory allergy: A real-world study. (PubMed, Allergol Int) - "This real-world study demonstrated the effectiveness of treatment with 3-tree SLIT-liquid or birch SLIT-liquid in slowing the progression of birch-family pollen allergy. 3-tree SLIT-liquid covering a broader repertoire of epitopes mimicking natural exposure throughout the year may be valuable for patients sensitised to birch and/or alder and/or hazel pollen suffering from overlapping tree-pollen seasons."

Journal • Real-world evidence • Allergic Rhinitis • Allergy • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

A 300 IR 5-grass pollen sublingual immunotherapy tablet-specific systematic review and meta-analysis confirms its clinical benefits for patients with allergic rhinoconjunctivitis with or without asthma. (PubMed, World Allergy Organ J) - "No safety issues were reported. This product-specific meta-analysis reinforces the evidence of clinical benefits associated with the 300 IR 5-grass SLIT-tablet, suggesting its appropriateness as a therapeutic choice for patients with ARC, irrespective of concurrent asthma, and exhibiting a favorable safety profile."

Journal • Retrospective data • Review • Asthma • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases

Total protein concentration and stability of Amb a 1 in glycerinated ragweed sublingual immunotherapy stored at room temperature and refrigerated cold temperature. (PubMed, Vet Dermatol) - "These results demonstrate that storage of glycerinated SLIT formulations in refrigerated CT preserved the highest concentration of the specific allergen Amb a 1, suggesting that SLIT formulations containing short ragweed should be stored under refrigeration."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Allergen Immunotherapy for the Prevention and Treatment of Asthma. (PubMed, Clin Exp Allergy) - P4 | "For patients with severe asthma or other safety concerns, the combination of AIT and biologics offers very promising new treatment modalities for the management of allergic asthma. Trial Registration: clinicaltrials.gov identifier: NCT06027073."

Journal • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Evaluation of the Benefits of Sublingual AIT (PRACTIS) (clinicaltrials.gov) - P=N/A | N=1635 | Completed | Sponsor: Stallergenes Greer

New trial • Allergic Rhinitis • Immunology • Inflammation

Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data. (PubMed, World Allergy Organ J) - P2, P2/3, P3 | "The 300IR house dust mite (HDM) sublingual immunotherapy (SLIT) tablet is approved for treatment of HDM-induced allergic rhinitis (AR)...4 severe laryngopharyngeal reactions (2 requiring adrenaline/epinephrine) and 1 moderate eczema considered serious rapidly resolved with medications; no anaphylaxis was reported...Safety data from RCTs and more than 7 years of real-life experience confirmed the favorable safety profile of 300IR HDM-SLIT tablet in patients across different regions, regardless of age and asthma status. NCT00674700; Retrospectively registered 06 May 2008.NCT01199133; Retrospectively registered 09 September 2010.NCT01527188; Retrospectively registered 01 February 2012.NCT02443805; Registered 29 April 2015/EudraCT 2014-004223-46; Registered 16 September 2015.jRCT2080221872/JapicCTI-121917; Registered 01 August 2012.jRCT2080222929/JapicCTI-15298; Registered 04 August 2015."

Journal • P4 data • Allergic Rhinitis • Allergy • Asthma • Atopic Dermatitis • Dermatology • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Satisfaction, Qol and adherence of patients allergic to dust mites and/or pollens undergoing sublingual immunotherapy. (PubMed, Immunotherapy) - "Patients were highly satisfied and most of them adhered to SLIT, being forgetfulness the main non-adherence motive. SLIT is a quick effective treatment against persistent moderate-to-severe symptoms in ARC and asthma but it should been improve forgetfulness, as non-adherence reason."

Adherence • Journal • Allergic Rhinitis • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases

Coordinated specific IgG2 and IgE responses are associated with high clinical benefit of allergen immunotherapy with 300 IR house dust mite sublingual tablets in a large European cohort (EAACI 2024) - "Such differences between high responders and the other groups were not observed in subjects administered placebo. Conclusion This study confirmed with a more than four times larger population the previous finding that coordinated IgG2 and IgE responses are associated with a high clinical benefit of AIT with 300 IR HDM tablets."

Clinical • Allergic Rhinitis • Immunology • Inflammation

Effect of 300 IR house dust mite sublingual immunotherapy tablet in paediatric patients and relationship with disease activity (EAACI 2024) - "Conclusion In this post hoc analysis of a paediatric RCT, the greatest improvements were observed in the tertile in which patients showed higher disease activity during the evaluation period, hence reflecting the true effect of 300 IR HDM SLIT tablet. Such findings confirm the benefit of this treatment during the periods when the patient's symptoms are most troublesome."

Clinical • Allergic Rhinitis • Immunology • Inflammation

Short-term benefits of sublingual immunotherapy in routine clinical practice: Patient Benefit Index by class in the observational, prospective, longitudinal study PRACTIS (EAACI 2024) - "Conclusion This post hoc analysis in a large, real-world study showed the benefits of SLIT met expectations for about 90% of treated patients with AR/AA/AC regardless of their age and the causal allergen, with notably more than half of them showing a PBI score ≥2.5. Treatment duration had no impact on the benefit perceived by HDM and GP allergic patients receiving SLIT."

Clinical • Longitudinal study • Observational data • Allergic Rhinitis • Allergy • Immunology • Inflammation

Short-term benefits of sublingual immunotherapy in routine clinical practice: deciphering factors influencing the patient satisfaction in the observational, prospective, longitudinal study PRACTIS (EAACI 2024) - "Also, for patients following the prescription correctly, the probability of PBI ≥1 increased with OR = 6.97 [1.67; 29.06] compared to those who were unable to do so. Conclusion This large, real-world study showed the benefits of SLIT in patients with AR/AA/AC can be enhanced by compliance to treatment, suggesting that patient education should be pursued to achieve this goal."

Clinical • Late-breaking abstract • Longitudinal study • Observational data • Allergic Rhinitis • Allergy • Immunology • Inflammation

Sublingual immunotherapy for house dust mite allergy induces expansions of allergen-specific memory B cells expressing CD29 and downregulating IL4Rα (EAACI 2024) - "Lower levels of IL4Rα might render the cells less responsive to type 2 immune signals and contribute to the observed desensitization. In ongoing studies, the kinetics of immune memory changes, as well as the functional relevance of the immunophenotypical changes, are studied."

IO biomarker • Allergy • Immunology • FCER2 • ITGB1

300 IR 5-grass pollen sublingual immunotherapy tablet for allergic rhinoconjunctivitis: A systematic review and meta-analysis of randomised studies (EAACI 2024) - "J Clin Epidemiol. 2022; 142: 200–208."

Retrospective data • Review • Immunology

Carry-over effect of 300 IR house dust mite sublingual immunotherapy tablet and relationship with disease activity: a post hoc analysis (EAACI 2024) - "Conclusion In this RCT, efficacy of 300 IR HDM SLIT tablet was demonstrated during treatment and maintained over the post-treatment year, with the greatest improvements observed in the tertile wherein patients reflected a higher disease activity corresponding to most troublesome symptoms. The tertile approach provides more accurate and meaningful measurements of efficacy and benefit for patients."

Retrospective data • Allergic Rhinitis • Immunology • Inflammation

Prospective, pilot, phase 1 study of iPUMP© in patients starting sublingual allergen immunotherapy (Staloral©) (EAACI 2024) - "It is easy to use and the functions in the connected device and app. can be consulted by patients to monitor their own compliance."

Clinical • Late-breaking abstract • P1 data • Allergic Rhinitis • Allergy • Immunology • Inflammation

Impact of liquid sublingual immunotherapy with mixed pollen allergens on asthma prevention in polyallergic patients: results from the real-world EfficAPSI study (EAACI 2024) - "Expert Rev Clin Immunol. 2023; doi: 10.1080/1744666X.2023.2294040"

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Allergic Rhinitis • Immunology • Inflammation

LILRA5 and CCL25 as candidate predictive biomarkers of AIT efficacy (EAACI 2024) - "Background Allergen immunotherapy (AIT) is recognised as a safe and efficacious treatment for type I respiratory allergies...When focusing on polysensitised patients with asthma, we observed an improvement in ROC analyses with area under curves reaching 0.84 and 0.7 for LILRA5 and CCL25, respectively. Conclusion Altogether, our findings clearly identify that the levels of LILRA5 and CCL25 in the blood before AIT serve as a reflection of the patient's inflammatory status, thus offering insights into the potential clinical responses expected during house dust mite immunotherapy."

Biomarker • Clinical • IO biomarker • Late-breaking abstract • Allergy • Immunology • Inflammation

Impact of liquid sublingual immunotherapy on asthma worsening prevention: GINA treatment stepping up results from the real-world EfficAPSI study (EAACI 2024) - "Expert Rev Clin Immunol. 2023; doi: 10.1080/1744666X.2023.2294040"

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Allergic Rhinitis • Allergy • Immunology • Inflammation

Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study). (PubMed, Lancet Reg Health Eur) - "The sensitive definition of asthma event considered the first asthma drug dispensation, hospitalisation or long-term disease (LTD) for asthma, the specific one omitted drug dispensation and the combined one considered omalizumab or three ICS ± LABA dispensation, hospitalisation or LTD. The use of three definitions (sensitive or specific) and GINA step-up reinforced the rigorous methodology, substantiating SLIT-liquid evidence as a causal treatment option for patients with respiratory allergies. Stallergenes Greer."

Journal • Allergic Rhinitis • Allergy • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

IR (index of reactivity)-house dust mite sublingual immunotherapy liquid formulation for allergic rhinoconjunctivitis: Systematic review and meta-analysis of randomized and nonrandomized studies. (PubMed, J Allergy Clin Immunol Glob) - "Metaregression showed that symptom improvement was correlated with treatment duration with consistent results in NRS and RCT with 12-month SS data: -0.87 (interquartile range, -1.02, -0.77) and -0.75 (interquartile range, -0.93, -0.41), respectively. This meta-analysis showed comparable clinical benefit of IR-HDM SLIT liquid formulation increasing over time in both NRS and RCT, suggesting that NRS may reliably integrate RCT results and be considered for guidelines."

Journal • Retrospective data • Review • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

A successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort. (PubMed, Expert Rev Clin Immunol) - "To date, the EfficAPSI cohort has the largest number of person-years of follow-up in the field of AIT. The completeness of the data allows to evaluate SLIT liquid effectiveness with rigorous methodology, leading to important insights on personalized medicine in real-life."

Journal • Reimbursement • US reimbursement • Allergic Rhinitis • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Deciphering Differential Behavior of Immune Responses as the Foundation for Precision Dosing in Allergen Immunotherapy. (PubMed, J Pers Med) - "A differential behavior in immune cells is clearly observed in responders, highlighting the importance of conducting clinical trials with large cohorts of well-characterized subjects to decipher the immune mechanism of AIT. We conclude that there is a need for designing new clinical and mechanistic studies to support the scientific rationale of dose adaptation in the interest of patients who do not properly respond to AIT."

Journal • Review • Allergy

Current advances in house dust mite allergen immunotherapy (AIT): Routes of administration, biomarkers and molecular allergen profiling. (PubMed, Mol Immunol) - "We also highlight recent data in more exploratory routes (i.e., oral, intralymphatic, epicutaneous and intradermal) and discuss respective advantages of various route, as well as their foreseen modes of action. Finally, we provide an update on biomarkers as well as on the relevance of the molecular profiling of allergic individuals related to treatment efficacy or asthma prediction."

Biomarker • IO biomarker • Journal • Allergy • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Early increase in serum specific IgG2 upon allergen immunotherapy with a 300 IR sublingual house dust mite tablet. (PubMed, Allergy) - No abstract available

Journal

Patient-reported outcome measures (PROMs) in birch pollen allergic patients treated with sublingual immunotherapy reflect real life. (PubMed, Allergy) - No abstract available

Journal • Patient reported outcomes